KR20220130085A - 테트라사이클릭 화합물 및 이의 염, 조성물, 및 이의 사용 방법 - Google Patents

테트라사이클릭 화합물 및 이의 염, 조성물, 및 이의 사용 방법 Download PDF

Info

Publication number
KR20220130085A
KR20220130085A KR1020227008247A KR20227008247A KR20220130085A KR 20220130085 A KR20220130085 A KR 20220130085A KR 1020227008247 A KR1020227008247 A KR 1020227008247A KR 20227008247 A KR20227008247 A KR 20227008247A KR 20220130085 A KR20220130085 A KR 20220130085A
Authority
KR
South Korea
Prior art keywords
compound
cancer
subject
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020227008247A
Other languages
English (en)
Korean (ko)
Inventor
존 숭
Original Assignee
센화 바이오사이언시즈 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 센화 바이오사이언시즈 인코포레이티드 filed Critical 센화 바이오사이언시즈 인코포레이티드
Publication of KR20220130085A publication Critical patent/KR20220130085A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020227008247A 2019-08-14 2020-08-14 테트라사이클릭 화합물 및 이의 염, 조성물, 및 이의 사용 방법 Withdrawn KR20220130085A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962886621P 2019-08-14 2019-08-14
US62/886,621 2019-08-14
US201962946774P 2019-12-11 2019-12-11
US62/946,774 2019-12-11
PCT/US2020/046329 WO2021030671A1 (en) 2019-08-14 2020-08-14 Tetracyclic compounds and their salts, compositions, and methods for their use

Publications (1)

Publication Number Publication Date
KR20220130085A true KR20220130085A (ko) 2022-09-26

Family

ID=74568302

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227008247A Withdrawn KR20220130085A (ko) 2019-08-14 2020-08-14 테트라사이클릭 화합물 및 이의 염, 조성물, 및 이의 사용 방법

Country Status (12)

Country Link
US (1) US20210046071A1 (https=)
EP (1) EP4013421A4 (https=)
JP (1) JP7566010B2 (https=)
KR (1) KR20220130085A (https=)
CN (1) CN114599368A (https=)
AU (1) AU2020328590B2 (https=)
BR (1) BR112022002784A2 (https=)
CA (1) CA3151112A1 (https=)
IL (1) IL290626A (https=)
PH (1) PH12022550360A1 (https=)
TW (1) TW202114694A (https=)
WO (1) WO2021030671A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7017509B2 (ja) 2015-11-20 2022-02-08 センワ バイオサイエンシズ インコーポレイテッド がんを治療するための四環式キノロン類似体の併用療法
CN112334133A (zh) 2018-02-15 2021-02-05 生华生物科技股份有限公司 喹诺酮类似物及其盐、组合物及其使用方法
CN114409681A (zh) * 2022-03-18 2022-04-29 信义核新(北京)生物科技有限公司 用于治疗dna损伤修复缺陷肿瘤的喹诺酮类似物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7928100B2 (en) * 2007-10-05 2011-04-19 Cylene Pharmaceuticals, Inc. Quinolone analogs and methods related thereto
US8853235B2 (en) * 2009-11-23 2014-10-07 Senhwa Biosciences, Inc. Polymorphs and salts of a kinase inhibitor
ES2754207T3 (es) * 2013-11-28 2020-04-16 Tel Hashomer Medical Res Infrastructure & Services Ltd Inhibidores de la ARN polimerasa I y usos de los mismos
JP7017509B2 (ja) * 2015-11-20 2022-02-08 センワ バイオサイエンシズ インコーポレイテッド がんを治療するための四環式キノロン類似体の併用療法
US9957282B2 (en) * 2015-12-14 2018-05-01 Senhwa Biosciences, Inc. Crystalline forms of quinolone analogs and their salts
JP2018537486A (ja) * 2015-12-14 2018-12-20 センワ バイオサイエンシズ インコーポレイテッド キノロン類似体及びその塩の結晶形
CN112334133A (zh) * 2018-02-15 2021-02-05 生华生物科技股份有限公司 喹诺酮类似物及其盐、组合物及其使用方法

Also Published As

Publication number Publication date
WO2021030671A1 (en) 2021-02-18
JP2022544559A (ja) 2022-10-19
US20210046071A1 (en) 2021-02-18
IL290626A (en) 2022-04-01
JP7566010B2 (ja) 2024-10-11
AU2020328590A1 (en) 2022-03-10
PH12022550360A1 (en) 2023-02-27
AU2020328590B2 (en) 2026-03-26
EP4013421A1 (en) 2022-06-22
EP4013421A4 (en) 2023-08-23
TW202114694A (zh) 2021-04-16
CA3151112A1 (en) 2021-02-18
CN114599368A (zh) 2022-06-07
BR112022002784A2 (pt) 2022-08-09

Similar Documents

Publication Publication Date Title
US20220088029A1 (en) Combination therapy of tetracyclic quinolone analogs for treating cancer
US11524012B1 (en) Quinolone analogs and their salts, compositions, and method for their use
RU2764116C2 (ru) Комбинация, содержащая палбоциклиб и 6-(2,4-дихлорфенил)-5-[4-[(3s)-1-(3-фторпропил)пиррролидин-3-ил]-8,9-дигидро-7h-бензо[7]аннулен-2-карбоновую кислоту, и ее применение для лечения рака
JP7566010B2 (ja) 四環式化合物及びそれらの塩、組成物、ならびにそれらの使用方法
CA2944255C (en) New derivatives of cephalosporin for treating cancer
US20220062294A1 (en) Pharmaceutical compositions of tetracyclic quinolone analogs and their salts
US20210046082A1 (en) Crystalline forms of quinoline analogs and salts thereof, compositions, and their methods for use
CN117794523A (zh) 使用parp抑制剂和plk1抑制剂的癌症治疗
HK1233924B (en) Derivatives of cephalosporin for treating cancer
HK1233924A1 (en) Derivatives of cephalosporin for treating cancer
HK1193754A (en) Combinations of akt and mek inhibitor compounds, and methods of use

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203